Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...
A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...
Use of certain dipeptidyl peptidase 4 (DPP-4) inhibitors appears to be associated with a small but significantly elevated risk for developing the chronic blistering skin condition bullous pemphigoid, ...
Please provide your email address to receive an email when new articles are posted on . Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical ...
Please provide your email address to receive an email when new articles are posted on . Bullous pemphigoid was the most prevalent autoimmune bullous disease in patients with coexistent psoriasis, ...
Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-filled blisters.
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...
DUBLIN--(BUSINESS WIRE)--The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Bullous Pemphigoid - Pipeline Insight, 2023" report ...
Dear Doctors: I am 75 years old, and two years ago, I was diagnosed with bullous pemphigoid. I understand this is an autoimmune problem. I also understand that this is more common in older people. I ...
Bullous pemphigoid is an autoimmune disease that causes painful chronic blisters and welts. The condition is rare, and typically affects older adults. Sufferers' average age is 80 and usually already ...
Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results